<DOC>
	<DOCNO>NCT00875524</DOCNO>
	<brief_summary>This trial evaluate use tetravalent vaccine dengue . Primary objective : - To describe immune response dengue vaccination tetravalent dengue vaccine adult , adolescent , child . - To evaluate safety vaccination sanofi pasteur 's tetravalent dengue vaccine 4 age cohort . - To evaluate persistence antibody dengue 5 year first vaccination sanofi pasteur 's tetravalent dengue vaccine four age cohort .</brief_summary>
	<brief_title>Study ChimeriVaxâ„¢ Tetravalent Dengue Vaccine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 2 45 year day inclusion . Provision Informed Consent/Assent Form sign subject ( and/or parent another legally acceptable representative subject &lt; 18 year ) . Subject ( parent/guardian subject &lt; 18 year ) able attend schedule visit comply trial procedure . For female subject childbearing potential , avoid become pregnant ( use effective method contraception abstinence ) least 4 week prior first vaccination , least 4 week last vaccination . Subject good health , base medical history , physical examination laboratory parameter . Exclusion Criteria : Personal family history thymic pathology ( thymoma ) , thymectomy , myasthenia . For female subject childbearing potential , known pregnancy positive serum pregnancy test Screening . For female subject childbearing potential , known pregnancy positive urine pregnancy test day first injection . Breastfeeding female subject . Receipt vaccine 4 week precede first trial vaccination . Human immunodeficiency virus , hepatitis B , hepatitis C seropositivity blood sample take screening . Planned participation another clinical trial first year study . Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within past 6 month , longterm systemic corticosteroid therapy . Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Chronic illness stage could interfere trial conduct completion , opinion Investigator . Current alcohol abuse drug addiction may interfere subject 's ability comply trial procedure . Receipt blood bloodderived product past 3 month might interfere assessment immune response . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent . Laboratory abnormality least moderate severity clinically significant accord Investigator blood sample take screening . Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination . Planned receipt vaccine 4 week follow first trial vaccination . Familial atopy medical history ( parent , brother , sister ) . Previous vaccination meningococcal A+C typhoid vaccine within 3 year prior inclusion . History meningococcal typhoid infection ( confirm either clinically , serologically microbiologically ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Dengue virus</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue disease</keyword>
	<keyword>Dengue vaccine</keyword>
</DOC>